Literature DB >> 12508476

[Faropenem 300 mg 3 times daily versus levofloxacin 100 mg 3 times daily in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy].

Tetsuro Muratani1, Kiyotaka Iihara, Takehisa Nishimura, Hisato Inatomi, Naohiro Fujimoto, Tomoko Kobayashi, Yoji Yamada, Koichi Takahashi, Tetsuro Matsumoto.   

Abstract

Faropenem (FRPM) is an only penem antibiotics. Though it has been reported that FRPM had good efficacy (overall efficacy rate: 82.0%) against patients with complicated urinary tract infection, FRPM has not been frequently used for UTI patients. This multicenter clinical study was designed to compare FRPM 300 mg 3 times daily to Levofloxacin (LVFX), which is the standard treatment for patients with UTI, 100 mg 3 times daily for 7 days in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy. A total of 60 patients with significant bacteriuria and pyuria were included in this study. Overall efficacy rate (excellent plus moderate) was achieved in 90.6% (29/32) of patients treated with FRPM versus 82.1% (23/28) of those treated with LVFX. The ratios of eliminated bacteriuria and cleared pyuria were 71.9% and 56.3% of patients treated with FRPM, and 64.3% and 75.0% of those treated with LVFX. These data were not significant difference. In conclusion, FRPM 300 mg 3 times daily is at least as effective as LVFX 100 mg 3 times daily in patients with complicated urinary tract infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12508476     DOI: 10.11150/kansenshogakuzasshi1970.76.928

Source DB:  PubMed          Journal:  Kansenshogaku Zasshi        ISSN: 0387-5911


  1 in total

1.  In Vitro Activity and Clinical Efficacy of Faropenem against Third-Generation Cephalosporin-Resistant Escherichia coli and Klebsiella pneumoniae.

Authors:  Kazuhiro Ishikawa; Yuki Uehara; Nobuyoshi Mori; Yumiko Mikami; Sayuri Tokioka; Daiki Kobayashi; Hisa Goke; Tatsuya Inukai; Aki Sakurai; Yohei Doi; Sayoko Kawakami; Shizuo Kayama; Motoyuki Sugai; Shigeki Nakamura
Journal:  Antimicrob Agents Chemother       Date:  2022-06-01       Impact factor: 5.938

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.